Last updated: January 26, 2026
Executive Summary
Amarin Pharma, Inc. initiated patent infringement litigation against Hikma Pharmaceuticals USA Inc. in the U.S. District Court for the District of Delaware (Case No. 1:20-cv-01630). The suit concerns Hikma’s attempts to market a generic version of Amarin’s flagship drug, Vascepa (icosapent ethyl), which is protected by several patents. The case highlights legal battles over patent validity, infringement, and the scope of patent claims related to pharmaceutical formulations. As of the most recent proceedings, the court has issued preliminary rulings on motions to dismiss and claims construction, shaping the case’s trajectory.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Amarin Pharma Inc.
Defendant: Hikma Pharmaceuticals USA Inc. |
| Court |
United States District Court, District of Delaware |
| Case Number |
1:20-cv-01630 |
| Filing Date |
June 4, 2020 |
| Nature |
Patent infringement and exclusivity dispute involving generic icosapent ethyl (Vascepa) |
Claims and Patent Overview
Amarin’s Asserted Patents
- U.S. Patent No. 9,375,413 – covering specific formulations and methods of making Vascepa.
- U.S. Patent No. 9,683,542 – related to methods of increasing omega-3 fatty acids concentration.
- U.S. Patent No. 10,939,004 – covering formulations and manufacturing processes.
Hikma’s Alleged Infringement
- Hikma’s filing seeking FDA approval for generic icosapent ethyl, challenging patent enforceability and scope.
- Allegation that Hikma’s product infringes on Amarin’s patent claims.
Legal Context
- Amarin's patents are part of an exclusivity arrangement under the Hatch-Waxman Act, aimed at protecting innovation while enabling generic competition after patent expiry or invalidation.
- The litigation follows Hikma’s Abbreviated New Drug Application (ANDA) submission, initiating patent challenges.
Procedural History and Court Rulings
Initial Complaint and Pleadings (2020)
- Filed June 4, 2020, alleging infringement and seeking injunctive relief.
- Hikma responded with motions to dismiss claims for patent invalidity and non-infringement.
Key Motions and Decisions
| Date |
Motion |
Court Decision |
Notes |
| December 2020 |
Hikma’s Motion to Dismiss |
Partially granted |
Court dismissed some claims related to patent scope but allowed others to proceed. |
| March 2021 |
Amarin’s Motion for Patent Construction |
Granted in part |
Court clarified claim scope for licensed patents. |
| June 2021 |
Summary Judgment Motions |
Pending |
Discussions on patent validity and infringement. |
Recent Developments
- The court has set a schedule for claim construction hearings scheduled for Q2 2023.
- Patent validity issues are under review following summary judgment briefing.
Patent Litigation Analysis
Validity Challenges
- Hikma’s primary defense challenges the novelty and non-obviousness of Amarin's patents, with prior art references including earlier omega-3 formulations and manufacturing procedures.
- Court has examined arguments based on 35 U.S.C. §§ 102 (novelty) and 103 (obviousness).
Infringement Analysis
- Amarin claims Hikma’s generic formulation infringes specific patent claims, especially concerning the dosing and formulation processes.
- Hikma argues their product falls outside patent claims due to differing manufacturing techniques or formulation compositions.
Claim Construction and Its Impact
- Critical to the case is how the court interprets patent language, particularly terms like "substantially pure" omega-3 fatty acids.
- The court tends to favor the patent holder’s interpretation but considers defendant’s arguments for narrower scope.
Potential Outcomes
| Scenario |
Implications |
Estimated Timeline |
| Patent upheld |
Delay or blocking of Hikma’s generic entry |
12-24 months (pending appeals) |
| Patent invalidated |
Hikma gains market entry |
6-12 months after decision |
| Settlement |
Licensing or market entry agreements |
Varies |
Comparative Analysis
| Aspect |
Amarin’s Position |
Hikma’s Defense |
| Patent Strength |
Strong, based on formulation specifics and manufacturing |
Argues claims are obvious or lack novelty |
| Infringement |
Clear, based on formulation similarity |
Disputed, with emphasis on process differences |
| Litigation Strategy |
Rely on patent validity and enforceability |
Focus on claim construction and prior art invalidity |
Legal and Market Implications
- The outcome hinges on patent validity, which could influence future patent drafting and patent office standards.
- It exemplifies the patent landscape for complex formulations as generics threaten exclusivity.
- A favorable ruling for Amarin could extend patent protections and delay generic competition beyond the 2027 expiration.
Deep Dive: Major Legal Issues
Patent Validity Challenges
- Patent attorneys debate the scope of "unexpected results" and inventive step.
- Prior art references include early omega-3 supplements and manufacturing disclosures.
Scope of Patent Claims
- How narrowly or broadly claim language is interpreted impacts infringement viability.
- Ambiguities in terms such as "substantially pure" can lead to contested claim scope.
Regulatory Hurdles
- FDA’s ANDA process triggers patent litigation under Hatch-Waxman, shaping strategy for both litigants.
- Generic applications requires demonstrating no patent infringement or invalidity.
Key Takeaways
- Patent infringement litigation in the pharmaceutical sector is heavily reliant on claim construction and validity assessments.
- Hikma’s challenge focuses on prior art and patent scope; Amarin emphasizes proprietary formulations.
- Court rulings on motions to dismiss and claim construction significantly influence case progression.
- Patent validity issues remain central; invalidation could open the market sooner, while upheld patents extend exclusivity.
- Companies should meticulously draft patent claims and consider strategic patent modeling during ANDA filings.
FAQs
Q1: What are the main legal grounds Hikma uses to challenge Amarin’s patents?
A1: Hikma challenges include arguments that the patents lack novelty and are obvious in light of prior omega-3 formulations, prior manufacturing techniques, and existing scientific disclosures.
Q2: How does patent claim construction affect the outcome of this litigation?
A2: The court’s interpretation of patent language determines whether Hikma’s product infringes and whether the patents are sufficiently broad or narrow, directly impacting legal defenses and patent enforceability.
Q3: What is the significance of the Hatch-Waxman Act in this case?
A3: Hatch-Waxman provides a pathway for generic manufacturers to challenge patents through ANDA and facilitates patent litigation, affecting timing and strategies for all parties involved.
Q4: Could the case set a precedent for pharmaceutical patent practices?
A4: Yes, especially regarding formulation claims and patent scope, influencing how patent claims are drafted and challenged in future complex patents.
Q5: When is a final ruling expected, and what are potential next steps?
A5: Outcomes depend on ongoing claim construction and validity rulings; expect final judgments within 12-24 months, subject to appeal or settlement discussions.
References
[1] Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc., 1:20-cv-01630 (D. Del.).
[2] U.S. Patent No. 9,375,413 (filed 2013).
[3] U.S. Patent No. 9,683,542 (filed 2014).
[4] U.S. Patent No. 10,939,004 (filed 2017).
[5] Hatch-Waxman Act, 35 U.S.C. §§ 271, 271(e).
